Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Induction Therapy With Docetaxel, Cisplatin and Fluorouracil in Nasal Cavity and Paranasal Sinus Cancer
NCT00707473Phase 2Terminated
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Jun 2008
- Primary completion
- Jun 2026
- Modality
- Nanoparticles, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of docetaxel, Cisplatin micelle injection (HA132), fluorouracil in nasal cavity cancer, Paranasal Sinus Cancer (NPSC), sponsored by University of Texas MD Anderson Cancer Center. Started Jun 2008; status: terminated.
02
Drugs
docetaxelCisplatin micelle injection (HA132)fluorouracil
03
Conditions
nasal cavity cancerParanasal Sinus Cancer (NPSC)
Beyond the preview
Go deeper on NCT00707473.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00707473.